Responsibility reports

We report on a wide range of data in our Responsible Business Report and provide additional ratings and disclosures below.

Latest reports

The Responsible Business Report includes our performance across our six priority areas, and includes data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2025.

Science Image Multiple Myeloma RGB

Our position on

Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.

Responsibility reports archive

Search our archive of responsible business reports and resources dating back to 2002.

 

Responsible business ratings

We regularly review our responsible business ratings to ensure the external benchmarks listed remain high quality, appropriate and relevant to stakeholders. Last updated July 2026.

External benchmarking

Current rating

Previous rating

Comments

Access to Medicines Index

3.72

4.06

Second in the Index, updated bi-annually, current results from November 2024. Scores range from 1 to 5, with 5 being the highest (best) score

Antimicrobial Resistance Benchmark

77%

84%

Led the benchmark since its inception in 2018; Current ranking updated March 2026

CDP Climate Change

A

A

Updated annually, current score updated December 2025

CDP Water Security

A

A

Updated annually, current score updated December 2025

CDP Supplier engagement rating

Leader

Leader

Updated annually, current score updated May 2026

Sustainalytics

Low risk

Low risk

2nd percentile in pharma subindustry group. Current rating as at July 2026

ISS Corporate Rating

B+

B+

Ranked 1st in our peer group. Latest profile update May 2026

FTSE4Good

Member 

Member 

Member since 2004, latest review in July 2026

 

Disclosure